

# Biosimilars Market, 2012 to 2023

<https://marketpublishers.com/r/B3201109C7DEN.html>

Date: January 2018

Pages: 192

Price: US\$ 4,400.00 (Single User License)

ID: B3201109C7DEN

## Abstracts

Biosimilars Market: By-Drug Class (Monoclonal Antibodies, Recombinant Hormones, Recombinant Growth Factors, Immunomodulators, Anti-Inflammatory Agents, and Others), By Application (Oncology, Blood Disorders, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Diabetes, and Others), By Manufacturing Type (Captive and Out-sourcing), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

### Global Biosimilars Market Report Description:

Global biosimilars market report gives a comprehensive outlook on biosimilars products across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on biosimilars market gives historical, current, and future market sizes (US\$ Mn) on the basis of product type, application, manufacturing type, distribution channel, and geographic regions. This report studies biosimilars market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, biosimilars market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed biosimilars market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the biosimilars market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescription of biosimilar products.

### Global Biosimilars Market:

Global biosimilars market estimated to be valued US\$ 4.10 Bn in 2017 and poised to grow at CAGR of 23.0% over 2017-2023. A market for biosimilars projected to reach US\$ 14.23 Bn by 2023 owing to increasing patent expires of biologics and rising biosimilars product pipeline.

Growing demand for cost-effective medications to reduce healthcare burden is driving the market revenue growth

Global biosimilars market is gaining traction in recent times owing to its cost-effective pricing in comparison with patented or branded biologics, which are generally priced higher than biologics. The adoption of cost-effective biosimilars is rising in different healthcare setups across the developed and developing countries to curtail the growing pressure on healthcare budgets. The introduction of biosimilars has even led to improved access to the premium-priced biopharmaceuticals in developing and underdeveloped markets with lesser costs. Moreover, favourable government policies to promote cost-effective biosimilars expected to drive market revenue growth over the forecast period.

Increasing prevalence of several chronic diseases are expected to drive biosimilars market revenue growth over the forecast period

The rising prevalence of several chronic diseases such as cancer, diabetes, cardiovascular diseases, autoimmune disease, and among others across the developed and developing economies expected to drive the market for Biosimilars Market over the forecast period. The growing demand from developing and an underdeveloped market for improved healthcare access are driving the market revenue growth over the forecast period. Moreover, several players are increasing their focus from developed markets to developing markets to tap increasingly growing market opportunity is driving the market revenue growth. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide.

Europe emerged as prominent region for Biosimilars market across the globe

Europe market expected to hold the higher revenue share in global biosimilars market owing to healthcare practitioners shift to low priced drugs, and wider treatment choices available in the region. Asia-Pacific biosimilars market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to large out-of-

pocket healthcare expenditure and large medical unmet need due to lack of patented product availability.

### Competition Assessment

Key players profiled in the global Biosimilars market include:

Amgen Inc. (U.S.)  
Biocon Ltd. (India)  
Celltrion, Inc. (South Korea)  
Dr Reddy's Laboratories Ltd. (India)  
F. Hoffmann-La Roche Ltd. (Switzerland)  
Pfizer Inc. (U.S.)  
Samsung Bioepis (South Korea)  
Novartis AG (Switzerland)  
Teva Pharmaceuticals Industries Ltd. (Israel)

Players in biosimilars market are focusing on introducing low-cost biosimilars in developed and developing economies to garner larger market revenue share in global biosimilars market. For instance, in 2015 Sandoz (Novartis AG) launched generic version (Glatopa) of copaxone (glatiramer acetate) in U.S. market.

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL BIOSIMILARS MARKET INTRODUCTION**

#### 2.1. Global Biosimilars Market – Taxonomy

#### 2.2. Global Biosimilars Market –Definitions

##### 2.2.1. Drug Class

##### 2.2.2. Application

##### 2.2.3. Manufacturing Type

##### 2.2.4. Distribution Channel

### **3. GLOBAL BIOSIMILARS MARKET DYNAMICS**

#### 3.1. Drivers

#### 3.2. Restraints

#### 3.3. Opportunities/Unmet Needs of the Market

#### 3.4. Trends

#### 3.5. Global Biosimilars Market Dynamics – Factors Impact Analysis

#### 3.6. Global Biosimilars Market – Regulations

##### 3.6.1. U.S.

##### 3.6.2. Europe

### **4. GLOBAL BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

#### 4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 4.3. Market Opportunity Analysis

### **5. GLOBAL BIOSIMILARS MARKET , BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 5.1. Monoclonal Antibodies

##### 5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

##### 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

##### 5.1.3. Market Opportunity Analysis

#### 5.2. Recombinant Hormones

- 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.2.3. Market Opportunity Analysis
- 5.3. Recombinant Growth Factors
  - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.3.3. Market Opportunity Analysis
- 5.4. Immunomodulators
  - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.4.3. Market Opportunity Analysis
- 5.5. Anti-Inflammatory Agents
  - 5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.5.3. Market Opportunity Analysis
- 5.6. Others
  - 5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.6.3. Market Opportunity Analysis

## **6. GLOBAL BIOSIMILARS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 6.1. Oncology
  - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.1.3. Market Opportunity Analysis
- 6.2. Blood Disorders
  - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.2.3. Market Opportunity Analysis
- 6.3. Autoimmune Diseases
  - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.3.3. Market Opportunity Analysis
- 6.4. Growth Hormone Deficiency
  - 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.4.3. Market Opportunity Analysis

## 6.5. Infectious Diseases

6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.3. Market Opportunity Analysis

## 6.6. Diabetes

6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.6.3. Market Opportunity Analysis

## 6.7. Others

6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.7.3. Market Opportunity Analysis

# **7. GLOBAL BIOSIMILARS MARKET FORECAST, BY MANUFACTURING TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

## 7.1. Captive

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

## 7.2. Out-sourcing

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

# **8. GLOBAL BIOSIMILARS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023**

## 8.1. Hospital Pharmacies

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

## 8.2. Retail Pharmacies

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

## 8.3. Online Pharmacies

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

### 8.3.3. Market Opportunity Analysis

## **9. GLOBAL BIOSIMILARS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 9.1. North America

9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.1.3. Market Opportunity Analysis

### 9.2. Europe

9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.2.3. Market Opportunity Analysis

### 9.3. Asia-Pacific

9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.3.3. Market Opportunity Analysis

### 9.4. Latin America

9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.4.3. Market Opportunity Analysis

### 9.5. Middle East and Africa

9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.5.3. Market Opportunity Analysis

9.6. Global Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Region, 2017 – 2023

## **10. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Monoclonal Antibodies

10.1.2. Recombinant Hormones

10.1.3. Recombinant Growth Factors

10.1.4. Immunomodulators

10.1.5. Anti-Inflammatory Agents

10.1.6. Others



## 10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.2.1. Oncology
- 10.2.2. Blood Disorders
- 10.2.3. Autoimmune Diseases
- 10.2.4. Growth Hormone Deficiency
- 10.2.5. Infectious Diseases
- 10.2.6. Diabetes
- 10.2.7. Others

## 10.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.3.1. Captive
- 10.3.2. Out-sourcing

## 10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies

## 10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

- 10.5.1. U.S.
- 10.5.2. Canada

## 10.6. North America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023

## 10.7. North America Biosimilars Market Dynamics – Trends

# **11. EUROPE BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

## 11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 11.1.1. Monoclonal Antibodies
- 11.1.2. Recombinant Hormones
- 11.1.3. Recombinant Growth Factors
- 11.1.4. Immunomodulators
- 11.1.5. Anti-Inflammatory Agents
- 11.1.6. Others

## 11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)



- 11.2.1. Oncology
- 11.2.2. Blood Disorders
- 11.2.3. Autoimmune Diseases
- 11.2.4. Growth Hormone Deficiency
- 11.2.5. Infectious Diseases
- 11.2.6. Diabetes
- 11.2.7. Others
- 11.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 11.3.1. Captive
  - 11.3.2. Out-sourcing
- 11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 11.4.1. Hospital Pharmacies
  - 11.4.2. Retail Pharmacies
  - 11.4.3. Online Pharmacies
- 11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 11.5.1. Germany
  - 11.5.2. UK
  - 11.5.3. France
  - 11.5.4. Spain
  - 11.5.5. Italy
  - 11.5.6. Russia
  - 11.5.7. Poland
  - 11.5.8. Rest of Europe
- 11.6. Europe Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
- 11.7. Europe Biosimilars Market Dynamics – Trends

## **12. ASIA-PACIFIC BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 12.1.1. Monoclonal Antibodies
  - 12.1.2. Recombinant Hormones
  - 12.1.3. Recombinant Growth Factors
  - 12.1.4. Immunomodulators

12.1.5. Anti-Inflammatory Agents

12.1.6. Others

12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Oncology

12.2.2. Blood Disorders

12.2.3. Autoimmune Diseases

12.2.4. Growth Hormone Deficiency

12.2.5. Infectious Diseases

12.2.6. Diabetes

12.2.7. Others

12.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Captive

12.3.2. Out-sourcing

12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

12.5.1. Japan

12.5.2. China

12.5.3. India

12.5.4. ASEAN

12.5.5. Australia & New Zealand

12.5.6. Rest of Asia-Pacific

12.6. Asia-Pacific Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023

12.7. Asia- Pacific Biosimilars Market Dynamics – Trends

## **13. LATIN AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Monoclonal Antibodies

- 13.1.2. Recombinant Hormones
- 13.1.3. Recombinant Growth Factors
- 13.1.4. Immunomodulators
- 13.1.5. Anti-Inflammatory Agents
- 13.1.6. Others
- 13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 13.2.1. Oncology
  - 13.2.2. Blood Disorders
  - 13.2.3. Autoimmune Diseases
  - 13.2.4. Growth Hormone Deficiency
  - 13.2.5. Infectious Diseases
  - 13.2.6. Diabetes
  - 13.2.7. Others
- 13.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 13.3.1. Captive
  - 13.3.2. Out-sourcing
- 13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 13.4.1. Hospital Pharmacies
  - 13.4.2. Retail Pharmacies
  - 13.4.3. Online Pharmacies
- 13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 13.5.1. Brazil
  - 13.5.2. Mexico
  - 13.5.3. Argentina
  - 13.5.4. Venezuela
  - 13.5.5. Rest of Latin America
- 13.6. Latin America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
- 13.7. Latin America Biosimilars Market Dynamics – Trends

## **14. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 14.1.1. Monoclonal Antibodies
- 14.1.2. Recombinant Hormones
- 14.1.3. Recombinant Growth Factors
- 14.1.4. Immunomodulators
- 14.1.5. Anti-Inflammatory Agents
- 14.1.6. Others
- 14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.2.1. Oncology
  - 14.2.2. Blood Disorders
  - 14.2.3. Autoimmune Diseases
  - 14.2.4. Growth Hormone Deficiency
  - 14.2.5. Infectious Diseases
  - 14.2.6. Diabetes
  - 14.2.7. Others
- 14.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.3.1. Captive
  - 14.3.2. Out-sourcing
- 14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 14.4.1. Hospital Pharmacies
  - 14.4.2. Retail Pharmacies
  - 14.4.3. Online Pharmacies
- 14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  - 14.5.1. Gulf Cooperation Council (GCC) Countries
  - 14.5.2. Israel
  - 14.5.3. South Africa
  - 14.5.4. Rest of MEA
- 14.6. MEA Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
- 14.7. MEA Biosimilars Market Dynamics – Trends

## **15. COMPETITION LANDSCAPE**

- 15.1. Strategic Dashboard of Top Market Players
- 15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. Amgen Inc. (U.S.)

15.2.2. Biocon Ltd. (India)

15.2.3. Celltrion, Inc. (South Korea)

15.2.4. Dr Reddy's Laboratories Ltd. (India)

15.2.5. F. Hoffmann-La Roche Ltd. (Switzerland)

15.2.6. Pfizer Inc. (U.S.)

15.2.7. Samsung Bioepis (South Korea)

15.2.8. Novartis AG (Switzerland)

15.2.9. Teva Pharmaceuticals Industries Ltd. (Israel)

## **16. RESEARCH METHODOLOGY**

## **17. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Biosimilars Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/B3201109C7DEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3201109C7DEN.html>